Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans

Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
Drug Metabolism and Disposition January 18, 2023, DMD-AR-2022-001099; DOI: https://doi.org/10.1124/dmd.122.001099
Ulrik Jurva
1Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Ulrik.jurva@astrazeneca.com
Lars Weidolf
2iMed CVMD DMPK, AstraZeneca R&D Molndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann-Sofie Sandinge
1Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carina Leandersson
3Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anja Ekdahl
1Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue-Qing Li
4CVMD iMed DMPK, AstraZeneca R&D Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Antonsson
5Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Sundell
5Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina Westerlund
5Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Amilon
6Formerly of Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM) BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tord Inghardt
5Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Sashi Gopaul
7Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca R&D Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

DMD-AR-2022-001099
DOI 
https://doi.org/10.1124/dmd.122.001099
PubMed 
36653117

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Published online January 18, 2023.

Article Versions

  • You are currently viewing an Earlier version of this article (January 18, 2023 - 08:18).
  • View the most recent version of this article
Copyright & Usage 
© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.

Author Information

  1. Ulrik Jurva1,*,
  2. Lars Weidolf2,
  3. Ann-Sofie Sandinge1,
  4. Carina Leandersson3,
  5. Anja Ekdahl1,
  6. Xue-Qing Li4,
  7. Thomas Antonsson5,
  8. Johan Sundell5,
  9. Kristina Westerlund5,
  10. Carl Amilon6,
  11. Tord Inghardt5, and
  12. V. Sashi Gopaul7
  1. 1Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  2. 2iMed CVMD DMPK, AstraZeneca R&D Molndal, Sweden
  3. 3Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Sweden
  4. 4CVMD iMed DMPK, AstraZeneca R&D Mölndal, Sweden
  5. 5Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Sweden
  6. 6Formerly of Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM) BioPharmaceuticals R&D, AstraZeneca, Sweden
  7. 7Early Research and Development Cardiovascular Renal and Metabolism, AstraZeneca R&D Gothenburg, Sweden
  1. ↵* Corresponding Author:
    Ulrik Jurva, Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, N/A, Sweden. E-mail: Ulrik.jurva{at}astrazeneca.com

Statistics from Altmetric.com

Article usage

Article usage: January 2023 to March 2023

AbstractFullPdf
Jan 202343820147
Feb 2023205377
Mar 202397055

Next
Back to top

In this issue

Drug Metabolism and Disposition: 51 (3)
Drug Metabolism and Disposition
Vol. 51, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Biotransformation of AZD4831 in animals and humans

Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
Drug Metabolism and Disposition January 18, 2023, DMD-AR-2022-001099; DOI: https://doi.org/10.1124/dmd.122.001099

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Biotransformation of AZD4831 in animals and humans

Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
Drug Metabolism and Disposition January 18, 2023, DMD-AR-2022-001099; DOI: https://doi.org/10.1124/dmd.122.001099
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics